It’s probably not a good idea to assume that even the savviest biotech investors know a PiggyBac transposition from a FLAER reagent, so the fact that the stocks of the three publicly traded CRISPR companies got hammered on Monday after a study (that included both!) questioned CRISPR’s safety might mean nothing. But as more scientists digested the news, it became clear this was no “OMG! Off-target effects!” erroneous report. Here’s why:

CRISPR-Cas9 did what it’s supposed to. Many of the concerns about this genome-editing technology have centered around off-target effects, in which the RNA that guides the DNA-cutting enzyme to its genomic bull’s eye mistakes the intended string of A’s, T’s, C’s, and G’s for a similar one.

Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Your daily dose of news in health and medicine

Privacy Policy